Piper Sandler analyst Yasmeen Rahimi initiated coverage with a Buy rating on Tenaya Therapeutics (TNYA – Research Report) today and set a price target of $40.00. The company’s shares opened today at $2.05.
Rahimi covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, Structure Therapeutics, Inc. Sponsored ADR, and Cytokinetics. According to TipRanks, Rahimi has an average return of 0.8% and a 33.16% success rate on recommended stocks.
Tenaya Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $21.33, representing a 940.49% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.
See today’s best-performing stocks on TipRanks >>
TNYA market cap is currently $139.1M and has a P/E ratio of -0.88.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TNYA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tenaya Therapeutics (TNYA) Company Description:
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
Read More on TNYA:
- Tenaya Therapeutics announces FDA clearance to begin testing of TN-401
- Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
- Tenaya Therapeutics management to meet virtually with Piper Sandler
- Tenaya Therapeutics presents clinical, preclinical data on TN-301 program
- Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
